DOCSLIB.ORG

Structural Study of the Acid Sphingomyelinase Protein Family

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Structural Study of the Acid Sphingomyelinase Protein Family Structural Study of the Acid Sphingomyelinase Protein Family Alexei Gorelik Department of Biochemistry McGill University, Montreal August 2017 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Alexei Gorelik, 2017 Abstract The acid sphingomyelinase (ASMase) converts the lipid sphingomyelin (SM) to ceramide. This protein participates in lysosomal lipid metabolism and plays an additional role in signal transduction at the cell surface by cleaving the abundant SM to ceramide, thus modulating membrane properties. These functions are enabled by the enzyme’s lipid- and membrane- interacting saposin domain. ASMase is part of a small family along with the poorly characterized ASMase-like phosphodiesterases 3A and 3B (SMPDL3A,B). SMPDL3A does not hydrolyze SM but degrades extracellular nucleotides, and is potentially involved in purinergic signaling. SMPDL3B is a regulator of the innate immune response and podocyte function, and displays a partially defined lipid- and membrane-modifying activity. I carried out structural studies to gain insight into substrate recognition and molecular functions of the ASMase family of proteins. Crystal structures of SMPDL3A uncovered the helical fold of a novel C-terminal subdomain, a slightly distinct catalytic mechanism, and a nucleotide-binding mode without specific contacts to their nucleoside moiety. The ASMase investigation revealed a conformational flexibility of its saposin domain: this module can switch from a detached, closed conformation to an open form which establishes a hydrophobic interface to the catalytic domain. This open configuration represents the active form of the enzyme, likely allowing lipid access to the active site. The SMPDL3B structure showed a narrow, boot-shaped substrate binding site that accommodates the head group of SM. However, no in vitro lipid hydrolysis could be detected; further work is required to identify potential bona fide substrates. In summary, these studies illustrate how an enzyme family can adapt a conserved architecture and mechanism to perform divergent functions. 2 Résume La sphingomyélinase acide (ASMase) produit le lipide céramide à partir de la sphingomyéline (SM). Cette protéine contribue au métabolisme des lipides dans le lysosome et participe à la transduction de signaux sur la membrane plasmique en altérant les propriétés de cette dernière par son action. Ces fonctions sont accomplies avec l’aide du domaine saposine de cette enzyme, qui interagit avec les lipides et les membranes. ASMase fait partie d’une famille de protéines dont les deux autres membres sont mal caractérisés : les phosphodiestérases SMPDL3A et B. SMPDL3A n’hydrolyse point la SM mais dégrade par contre les nucléotides extracellulaires, ce qui implique potentiellement cette enzyme dans la signalisation purinergique. SMPDL3B régule les réponses immunitaires innées ainsi que le fonctionnement des podocytes par l’entremise d’une activité incomplètement définie de modification de lipides et de membranes. J’ai mené des études structurales sur cette famille de protéines afin de mieux comprendre leurs fonctions moléculaires et la reconnaissance des substrats par ces enzymes. Les structures cristallines de SMPDL3A ont révélé le repliement hélicoïdal d’un nouveau sous-domaine C- terminal, un mécanisme catalytique légèrement modifié, et un mode de liaison aux nucléotides dénué de contacts spécifiques avec leur portion nucléoside. L’investigation de l’ASMase a démontré la flexibilité conformationnelle de son domaine saposine : ce module alterne entre une configuration fermée détachée, et une forme ouverte qui interagit avec le domaine catalytique via une interface hydrophobe. Cette conformation ouverte représente la forme active de la protéine, probablement en facilitant l’accès des lipides au site actif. La structure de SMPDL3B a dévoilé un site de liaison au substrat étroit en forme de botte, où le groupe de tête de la SM peut se positionner. Par contre, aucune hydrolyse de lipides n’a pu être démontrée in vitro; des travaux additionnels sont requis afin d’identifier des substrats authentiques. En résume, ces études illustrent la capacité d’une famille d’enzymes à adapter une structure et un mécanisme communs vers des fonctions variées. 3 Table of contents Abstract 2 Résumé 3 Table of contents 4 List of figures 7 List of tables 9 List of abbreviations 10 Preface 12 Author contributions 13 Acknowledgements 14 Chapter 1 – General introduction 15 1.1 The calcineurin-like phosphoesterases 15 1.1.1 Shared structural features 17 1.1.2 PPP-type phosphatases 20 1.1.3 Other serine/threonine phosphatases 20 1.1.4 Nucleases 21 1.1.5 Nucleotidases 21 1.1.6 Enzymes of other or unknown function 22 1.1.7 Bacterial enzymes 23 1.1.8 Acid sphingomyelinase-like proteins 23 1.2 Acid sphingomyelinase 24 1.2.1 Sphingolipids 24 1.2.2 Sphingomyelinases 26 1.2.3 Niemann-Pick disease types A and B 27 1.2.4 Lysosomal roles of ASMase 28 1.2.5 Saposins 29 1.2.6 Roles of ASMase at the cell surface 32 1.2.7 ASMase in the circulation 34 1.3 SMPDL3B 34 4 1.3.1 Lipid rafts in toll-like receptor signaling 35 1.3.2 ASMase in TLR signaling 35 1.3.3 SMPDL3B in TLR signaling 36 1.3.4 Lipid rafts in podocytes 38 1.3.5 SMPDL3B in podocyte function 38 1.3.6 SMPDL3B outside of the cell 40 1.4 SMPDL3A 41 1.4.1 SMPDL3A in the cholesterol response 41 1.4.2 Purinergic signaling 42 1.5 Conclusion 43 Chapter 2 – Study of SMPDL3A 45 Introductory transition 45 2.1 Abstract 46 2.2 Introduction 47 2.3 Results 49 2.4 Discussion 65 2.5 Experimental procedures 67 Concluding transition 69 Chapter 3 – Study of ASMase 74 Introductory transition 74 3.1 Abstract 75 3.2 Introduction 76 3.3 Results 78 3.4 Discussion 103 3.5 Experimental procedures 105 Concluding transition 109 Chapter 4 – Study of SMPDL3B 116 Introductory transition 116 5 4.1 Abstract 117 4.2 Introduction 118 4.3 Results 121 4.4 Discussion 134 4.5 Experimental procedures 138 Concluding transition 141 Chapter 5 – Conclusion 144 References 148 6 List of figures Figure 1.1 Mammalian members of the calcineurin-like phosphoesterase superfamily 16 Figure 1.2 Structural superimposition of calcineurin-like phosphoesterases 18 Figure 1.3 Active site of calcineurin-like phosphoesterases 19 Figure 1.4 Chemical structures of representative lipid species 25 Figure 1.5 Structural flexibility of saposins 31 Figure 2.1 Sequence alignment of SMPDL3A and ASMase 50 Figure 2.2 Structure of SMPDL3A 52 Figure 2.3 Active site of SMPDL3A 54 Figure 2.4 Inhibition of SMPDL3A by excess zinc 56 Figure 2.5 Ligands bound in the active site of SMPDL3A 58 Figure 2.6 Proposed reaction mechanism for SMPDL3A 61 Figure 2.7 Nucleotide binding modes of human and murine SMPDL3A 70 Figure 3.1 Structural overview of ASMase 79 Figure 3.2 The ASMase fold 81 Figure 3.3 Comparison and mutation of the ASMase active site and proposed catalytic mechanism 84 Figure 3.4 ASMasesap – ASMasecat interactions 87 Figure 3.5 Purification of murine ASMase and bNPP hydrolysis assay 90 Figure 3.6 Purification of human ASMase and activity assays 92 Figure 3.7 Main chain B-factor analysis of catalytic domain interface loops 94 Figure 3.8 Saposin dimers in the crystal lattice 96 Figure 3.9 Electrostatic surface and substrate binding site of ASMase 97 Figure 3.10 Liposomal activity assay of ASMase in the presence of cationic amphiphilic drugs (CADs) 98 Figure 3.11 Electron density and binding mechanism for the co-crystallized inhibitor AbPA 100 Figure 3.12 Structural mapping of disease mutations 102 Figure 3.13 Schematic for ASMase activation 104 7 Figure 3.14 Representative electron density maps of the ASMase structures 108 Figure 3.15 PC recognition by human ASMase 110 Figure 3.16 Lipid delivery to GALC by SapA 112 Figure 4.1 Crystal structure of SMPDL3B 122 Figure 4.2 Structural comparison of SMPDL3B, SMPDL3A and ASMase 124 Figure 4.3 Region around active site 126 Figure 4.4 Phosphocholine bound in the active site of SMPDL3B 128 Figure 4.5 In vitro enzymatic activity against various substrates 130 Figure 4.6 Functional impact of SMPDL3B mutants on LPS-induced IL-6 release in macrophages 133 Figure 4.7 Proposed binding modes of potential substrates 136 Figure 4.8 Putative rituximab epitope on SMPDL3B 142 8 List of tables Table 2.1 SMPDL3A X-ray data collection and structure refinement statistics 71 Table 2.2 Michaelis-Menten parameters of ATP hydrolysis by SMPDL3A 73 Table 3.1 ASMase X-ray data collection and structure refinement statistics 78 Table 3.2 Predicted effects of ASMase mutations found in Niemann-Pick patients 101 Table 3.3 Predicted effects of ASMase variants of unknown significance 115 Table 4.1 SMPDL3B X-ray data collection and structure refinement statistics 143 9 List of abbreviations AbPA – 1-aminodecylidene bis-phosphonic acid alk-SMase – alkaline sphingomyelinase AMPCPP – ɑ,β-methylene ATP AP4A – diadenosine tetraphosphate ASMase – acid sphingomyelinase BMP – bis(monoacylglycero)phosphate bNPP – bis(4-nitrophenyl) phosphate CAD – cationic amphiphilic drug CTD – C-terminal domain / subdomain DKD – diabetic kidney disease E-NPP – ecto-nucleotide pyrophosphatase / phosphodiesterase E-NTPD – ecto-nucleoside triphosphate diphosphohydrolase ERT – enzyme replacement therapy FSGS – focal segmental glomerulosclerosis GPI – glycosylphosphatidylinositol IL-6 – interleukin-6 LDL – low density lipoprotein LPS – lipopolysaccharide M6P – mannose-6-phosphate NP – Niemann-Pick NPPC – p-nitrophenylphosphorylcholine PC – phosphocholine pNP-PC – p-nitrophenyl phosphorylcholine pNP-TMP – p-nitrophenyl thymidine 5'-monophosphate SM – sphingomyelin SMase – sphingomyelinase SMPD1 – sphingomyelin phosphodiesterase 1 SMPDL3A – acid sphingomyelinase-like phosphodiesterase 3a SMPDL3B – acid sphingomyelinase-like phosphodiesterase 3b 10 suPAR – soluble urokinase-type plasminogen activator TLR – toll-like receptor TM – transmembrane TNFα – tumor necrosis factor α uPAR – urokinase-type plasminogen activator 11 Preface This is a manuscript-based thesis consisting of three published articles [211,221,228], in chronological order: Chapter 2 Gorelik A, Illes K, Superti-Furga G, Nagar B.
Load more

Recommended publications
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • Characterization of a Mutation in a Family with Saposin B Deficiency
    Proc. Nadl. Acad. Sci. USA Vol. 87, pp. 2541-2544, April 1990 Genetics Characterization of a mutation in a family with saposin B deficiency: A glycosylation site defect (sphingolipid activator protein/SAP-1/metachromatic leukodystrophy/arylsulfatase A) KEITH A. KRETZ*, GEOFFREY S. CARSON*, SATOSHI MORIMOTO*t, YASUO KISHIMOTO*, ARVAN L. FLUHARTYt, AND JOHN S. O'BPUEN*§ *Department of Neurosciences and Center for Molecular Genetics, University of California, San Diego, School of Medicine, M-034J, La Jolla, CA 92093; and tUniversity of California, Los Angeles, Mental Retardation Research Center Group at Lanterman Developmental Center, Pomona, CA 91766 Communicated by Dan L. Lindsley, January 19, 1990 ABSTRACT Saposins are small, heat-stable glycoproteins these four saposin proteins has now been isolated and their required for the hydrolysis of sphingolipids by specific lyso- activating properties have been determined (3-14). somal hydrolases. Saposins A, B, C, and D are derived by Saposins A and C specifically activate hydrolysis of glu- proteolytic processing from a single precursor protein named cocerebroside byB-glucosylceramidase (D-glucosyl-N-acyl- prosaposin. Saposin B, previously known as SAP-1 and sul- sphingosine glucohydrolase; EC 3.2.1.45) and ofgalactocere- fatide activator, stimulates the hydrolysis of a wide variety of broside by galactosylceramidase (D-galactosyl-N-acyl- substrates including cerebroside sulfate, GM1 ganglioside, and sphingosine galactohydrolase; EC 3.2.1.46) (3, 4). Saposin D globotriaosylceramide by arylsulfatase A, acid 8-galacto- specifically activates the hydrolysis of sphingomyelin by sidase, and a-galactosidase, respectively. Human saposin B sphingomyelin phosphodiesterase (sphingomyelin choline- deficiency, transmitted as an autosomal recessive trait, results phosphohydrolase; EC 3.1.4.12) (5).
    [Show full text]
  • Avicin G Is a Potent Sphingomyelinase Inhibitor and Blocks Oncogenic K- and H-Ras Signaling Christian M
    www.nature.com/scientificreports OPEN Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling Christian M. Garrido1, Karen M. Henkels1, Kristen M. Rehl1, Hong Liang2, Yong Zhou2, Jordan U. Gutterman3 & Kwang-jin Cho1 ✉ K-Ras must interact primarily with the plasma membrane (PM) for its biological activity. Therefore, disrupting K-Ras PM interaction is a tractable approach to block oncogenic K-Ras activity. Here, we found that avicin G, a family of natural plant-derived triterpenoid saponins from Acacia victoriae, mislocalizes K-Ras from the PM and disrupts PM spatial organization of oncogenic K-Ras and H-Ras by depleting phosphatidylserine (PtdSer) and cholesterol contents, respectively, at the inner PM leafet. Avicin G also inhibits oncogenic K- and H-Ras signal output and the growth of K-Ras-addicted pancreatic and non-small cell lung cancer cells. We further identifed that avicin G perturbs lysosomal activity, and disrupts cellular localization and activity of neutral and acid sphingomyelinases (SMases), resulting in elevated cellular sphingomyelin (SM) levels and altered SM distribution. Moreover, we show that neutral SMase inhibitors disrupt the PM localization of K-Ras and PtdSer and oncogenic K-Ras signaling. In sum, this study identifes avicin G as a new potent anti-Ras inhibitor, and suggests that neutral SMase can be a tractable target for developing anti-K-Ras therapeutics. Ras proteins are small GTPases that primarily localize to the inner-leafet of the plasma membrane (PM), switch- ing between an active GTP-bound state and inactive GDP-bound state1. In response to epidermal growth factor stimulation or receptor tyrosine kinase activation, guanine nucleotide exchange factors activate Ras by inducing the release of the guanine nucleotides and binding of GTP1.
    [Show full text]
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]
  • Assessment of a Targeted Gene Panel for Identification of Genes Associated with Movement Disorders
    Supplementary Online Content Montaut S, Tranchant C, Drouot N, et al; French Parkinson’s and Movement Disorders Consortium. Assessment of a targeted gene panel for identification of genes associated with movement disorders. JAMA Neurol. Published online June 18, 2018. doi:10.1001/jamaneurol.2018.1478 eMethods. Supplemental methods. eTable 1. Name, phenotype and inheritance of the genes included in the panel. eTable 2. Probable pathogenic variants identified in a cohort of 23 patients with cerebellar ataxia using WES analysis. eTable 3. Negative cases in a cohort of 23 patients with cerebellar ataxia studied using WES analysis. eTable 4. Variants of unknown significance (VUSs) identified in the cohort. eFigure 1. Examples of pedigrees of cases with identified causative variants. eFigure 2. Pedigrees suggesting mendelian inheritance in negative cases. eFigure 3. Examples of pedigrees of cases with identified VUSs. eResults. Supplemental results. This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 eMethods. Supplemental methods Patients selection In the multicentric, prospective study, patients were selected from 25 French, 1 Luxembourg and 1 Algerian tertiary MDs centers between September 2014 and July 2016. Inclusion criteria were patients (1) who had developed one or several chronic MDs (2) with an age of onset below 40 years and/or presence of a family history of MDs. Patients suffering from essential tremor, tic or Gilles de la Tourette syndrome, pure cerebellar ataxia or with clinical/paraclinical findings suggestive of an acquired cause were excluded.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Regulation of Microvesicle Particle Release in Keratinocytes
    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2018 Regulation of Microvesicle Particle Release in Keratinocytes Azeezat Afolake Awoyemi Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Pharmacology, Toxicology and Environmental Health Commons Repository Citation Awoyemi, Azeezat Afolake, "Regulation of Microvesicle Particle Release in Keratinocytes" (2018). Browse all Theses and Dissertations. 1999. https://corescholar.libraries.wright.edu/etd_all/1999 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. REGULATION OF MICROVESICLE PARTICLE RELEASE IN KERATINOCYTES A thesis submitted in partial fulfilment of the Requirements for the degree of Master of Science By AZEEZAT AFOLAKE AWOYEMI B.S., University of Lagos, 2015 2018 Wright State University i All rights reserved. This work may not be reproduced in whole or in part by photocopy or other means, without permission of the author. COPYRIGHT BY AZEEZAT AFOLAKE AWOYEMI 2018 ii WRIGHT STATE UNIVERSITY GRADUATE SCHOOL JULY 23, 2018 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY Azeezat Afolake Awoyemi ENTITLED Regulation of Microvesicle Particle release in keratinocytes. BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science. Jeffrey B. Travers, M.D., Ph.D. Thesis Director Jeffrey B. Travers, M.D., Ph.D. Chair, Department of Pharmacology and Toxicology Committee on Final Examination Jeffrey B Travers, M.D., Ph.D.
    [Show full text]
  • Cldn19 Clic2 Clmp Cln3
    NewbornDx™ Advanced Sequencing Evaluation When time to diagnosis matters, the NewbornDx™ Advanced Sequencing Evaluation from Athena Diagnostics delivers rapid, 5- to 7-day results on a targeted 1,722-genes. A2ML1 ALAD ATM CAV1 CLDN19 CTNS DOCK7 ETFB FOXC2 GLUL HOXC13 JAK3 AAAS ALAS2 ATP1A2 CBL CLIC2 CTRC DOCK8 ETFDH FOXE1 GLYCTK HOXD13 JUP AARS2 ALDH18A1 ATP1A3 CBS CLMP CTSA DOK7 ETHE1 FOXE3 GM2A HPD KANK1 AASS ALDH1A2 ATP2B3 CC2D2A CLN3 CTSD DOLK EVC FOXF1 GMPPA HPGD K ANSL1 ABAT ALDH3A2 ATP5A1 CCDC103 CLN5 CTSK DPAGT1 EVC2 FOXG1 GMPPB HPRT1 KAT6B ABCA12 ALDH4A1 ATP5E CCDC114 CLN6 CUBN DPM1 EXOC4 FOXH1 GNA11 HPSE2 KCNA2 ABCA3 ALDH5A1 ATP6AP2 CCDC151 CLN8 CUL4B DPM2 EXOSC3 FOXI1 GNAI3 HRAS KCNB1 ABCA4 ALDH7A1 ATP6V0A2 CCDC22 CLP1 CUL7 DPM3 EXPH5 FOXL2 GNAO1 HSD17B10 KCND2 ABCB11 ALDOA ATP6V1B1 CCDC39 CLPB CXCR4 DPP6 EYA1 FOXP1 GNAS HSD17B4 KCNE1 ABCB4 ALDOB ATP7A CCDC40 CLPP CYB5R3 DPYD EZH2 FOXP2 GNE HSD3B2 KCNE2 ABCB6 ALG1 ATP8A2 CCDC65 CNNM2 CYC1 DPYS F10 FOXP3 GNMT HSD3B7 KCNH2 ABCB7 ALG11 ATP8B1 CCDC78 CNTN1 CYP11B1 DRC1 F11 FOXRED1 GNPAT HSPD1 KCNH5 ABCC2 ALG12 ATPAF2 CCDC8 CNTNAP1 CYP11B2 DSC2 F13A1 FRAS1 GNPTAB HSPG2 KCNJ10 ABCC8 ALG13 ATR CCDC88C CNTNAP2 CYP17A1 DSG1 F13B FREM1 GNPTG HUWE1 KCNJ11 ABCC9 ALG14 ATRX CCND2 COA5 CYP1B1 DSP F2 FREM2 GNS HYDIN KCNJ13 ABCD3 ALG2 AUH CCNO COG1 CYP24A1 DST F5 FRMD7 GORAB HYLS1 KCNJ2 ABCD4 ALG3 B3GALNT2 CCS COG4 CYP26C1 DSTYK F7 FTCD GP1BA IBA57 KCNJ5 ABHD5 ALG6 B3GAT3 CCT5 COG5 CYP27A1 DTNA F8 FTO GP1BB ICK KCNJ8 ACAD8 ALG8 B3GLCT CD151 COG6 CYP27B1 DUOX2 F9 FUCA1 GP6 ICOS KCNK3 ACAD9 ALG9
    [Show full text]
  • Mouse Model of GM2 Activator Deficiency Manifests Cerebellar Pathology and Motor Impairment
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 8138–8143, July 1997 Medical Sciences Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment (animal modelyGM2 gangliosidosisygene targetingylysosomal storage disease) YUJING LIU*, ALEXANDER HOFFMANN†,ALEXANDER GRINBERG‡,HEINER WESTPHAL‡,MICHAEL P. MCDONALD§, KATHERINE M. MILLER§,JACQUELINE N. CRAWLEY§,KONRAD SANDHOFF†,KINUKO SUZUKI¶, AND RICHARD L. PROIA* *Section on Biochemical Genetics, Genetics and Biochemistry Branch, National Institute of Diabetes and Digestive and Kidney Diseases, ‡Laboratory of Mammalian Genes and Development, National Institute of Child Health and Development, and §Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892; †Institut fu¨r Oganische Chemie und Biochemie der Universita¨tBonn, Gerhard-Domagk-Strasse 1, 53121 Bonn, Germany; and ¶Department of Pathology and Laboratory Medicine, and Neuroscience Center, University of North Carolina, Chapel Hill, NC 27599 Communicated by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, May 12, 1997 (received for review March 21, 1997) ABSTRACT The GM2 activator deficiency (also known as disorder, the respective genetic lesion results in impairment of the AB variant), Tay–Sachs disease, and Sandhoff disease are the the degradation of GM2 ganglioside and related substrates. major forms of the GM2 gangliosidoses, disorders caused by In humans, in vivo GM2 ganglioside degradation requires the defective degradation of GM2 ganglioside. Tay–Sachs and Sand- GM2 activator protein to form a complex with GM2 ganglioside. hoff diseases are caused by mutations in the genes (HEXA and b-Hexosaminidase A then is able to interact with the activator- HEXB) encoding the subunits of b-hexosaminidase A.
    [Show full text]
  • Role of Acid Sphingomyelinase and IL-6 As Mediators Of
    Thorax Online First, published on July 27, 2016 as 10.1136/thoraxjnl-2015-208067 Respiratory research ORIGINAL ARTICLE Thorax: first published as 10.1136/thoraxjnl-2015-208067 on 27 July 2016. Downloaded from Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction Rachele Pandolfi,1,2,3 Bianca Barreira,1,2,3 Enrique Moreno,1,2,3 Victor Lara-Acedo,2 Daniel Morales-Cano,1,2,3 Andrea Martínez-Ramas,1,2,3 Beatriz de Olaiz Navarro,4 Raquel Herrero,1,5 José Ángel Lorente,1,5,6 Ángel Cogolludo,1,2,3 Francisco Pérez-Vizcaíno,1,2,3 Laura Moreno1,2,3 ▸ Additional material is ABSTRACT published online only. To view Background Pulmonary hypertension (PH) is frequently Key messages please visit the journal online (http://dx.doi.org/10.1136/ observed in patients with acute respiratory distress thoraxjnl-2015-208067). syndrome (ARDS) and it is associated with an increased risk of mortality. Both acid sphingomyelinase (aSMase) 1Ciber Enfermedades What is the key question? Respiratorias (CIBERES), activity and interleukin 6 (IL-6) levels are increased in ▸ Pulmonary hypertension and right ventricular Madrid, Spain patients with sepsis and correlate with worst outcomes, dysfunction are prominent prognostic features 2 Department of Pharmacology, but their role in pulmonary vascular dysfunction of acute respiratory distress syndrome (ARDS) School of Medicine, pathogenesis has not yet been elucidated. Therefore, the which, given the unclear pathophysiology and Universidad Complutense de Madrid, Madrid, Spain aim of this study was to determine the potential the lack of approved pharmacological therapies, 3Gregorio Marañón Biomedical contribution of aSMase and IL-6 in the pulmonary demand the identification of new therapeutic Research Institution (IiSGM), vascular dysfunction induced by lipopolysaccharide (LPS).
    [Show full text]
  • PFK-2/Fbpase-2: Maker and Breaker of the Essential Biofactor Fructose-2, 6-Bisphosphate
    30 Review TRENDS in Biochemical Sciences Vol.26 No.1 January 2001 PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2, 6-bisphosphate DavidA. Okar, Ànna Manzano,Aurèa Navarro-Sabatè, Lluìs Riera, Ramon Bartrons and Alex J. Lange Fructose-2,6-bisphosphate is responsible for mediating glucagon-stimulated extraction in base led to the discovery of F-2,6-P2 and gluconeogenesis in the liver.This discovery has led to the realization that this the realization that it was either formed or destroyed compound plays a significant role in directing carbohydrate fluxes in all during metabolic transitions where its concentration eukaryotes. Biophysical studies of the enzyme that both synthesizes and determined changes in glycolytic and gluconeogenic degrades this biofactor have yielded insight into its molecular enzymology. carbon flux in the liver. Interest in this compound grew Moreover, the metabolic role of fructose-2,6-bisphosphate has great potential rapidly because it was found to be a most potent in the treatment of diabetes. positive allosteric effector of 6-phosphofructo-1- kinase (PFK-1; EC 2.7.1.11) and an inhibitor of A trail that began with the discovery of a highly potent fructose-1,6-bisphosphatase (FBPase-1; EC 3.1.3.11). regulator of mammalian hepatic carbohydrate Because of its antagonistic actions on these enzymes, metabolism, fructose-2,6-bisphosphate (F-2,6-P2), led F-2,6-P2 plays a crucial role in the control of the to the discovery of the bifunctional enzyme opposing hepatic glycolytic and gluconeogenic 6-phosphofructo-2-kinase/fructose- pathways1–4 (Fig.
    [Show full text]
  • Abcam Enzymatic Activity Assay Kits
    Less haste, more speed 用更快的速度，從容的完成實驗 我們擁有品項齊全的抗體、相關免疫實驗試劑，以及數百種偵測酵素活性的試劑 Signal transduction Metabolism 套組，協助研究者進行訊號傳遞 ( )、代謝 ( )、神經 Neuroscience Gene regulation Epigenetics 科學 ( )、基因調控 ( )、表觀遺傳 ( )、 Cancer Cardiovascular Oxidative stress 癌症 ( )、心血管 ( )、氧化壓力 ( ) 等相關研 瀏覽相關產品目錄 Cell culture Tissue lysate 究。 涵蓋樣本來源諸如：細胞培養 ( )、組織裂解物 ( ) 或體 Body fluid 液 ( ) 等 。 我們總是追求卓越，完整呈現給您最佳的抗體與分析試劑盒， 以協助您快速取得所需的實驗結果。 Abcam 各項特惠活動進行中，詳情請洽 台灣代理 ― 伯森生技。 酵素測定成功秘訣 Activity assay kits 活性測定試劑套組 ( ) Target/ Protein Detection method Cat. no. Target/ Protein Detection method Cat. no. Acetylcholinesterase Colorimetric ab138871 Aldo-Keto Reductase Colorimetric ab211112 Acetylcholinesterase Fluorescent ab138872 Aldolase Colorimetric ab196994 Acetylcholinesterase Colorimetric/ ab138873 Alkaline Phosphatase Colorimetric ab83369 Fluorometric Alkaline Phosphatase Fluorescent ab83371 Acetyltransferase Fluorescent ab204536 Alkaline Phosphatase Fluorescent ab138887 Acid Phosphatase Colorimetric ab83367 Alkaline Phosphatase Luminescent ab233466 Acid Phosphatase Fluorescent ab83370 Alkaline Sphingomyelinase Colorimetric ab241039 Acid Sphingomyelinase Colorimetric ab252889 Alpha Galactosidase Fluorescent ab239716 Acidic Sphingomyelinase Fluorescent ab190554 Alpha-Glucosidase Colorimetric ab174093 Aconitase Colorimetric ab83459 Alpha-Ketoglutarate Dehydrogenase Colorimetric ab185440 Aconitase Colorimetric ab109712 Amylase Colorimetric ab102523 Adenosine Deaminase Fluorescent ab204695 Arginase Colorimetric ab180877 Adenosine Deaminase Colorimetric ab211093 Asparaginase Colorimetric/
    [Show full text]